Evolus (NASDAQ:EOLS – Get Free Report) and Acelyrin (NASDAQ:SLRN – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.
Institutional and Insider Ownership
90.7% of Evolus shares are held by institutional investors. Comparatively, 87.3% of Acelyrin shares are held by institutional investors. 6.1% of Evolus shares are held by insiders. Comparatively, 13.6% of Acelyrin shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Evolus and Acelyrin”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evolus | $202.09 million | 4.25 | -$61.69 million | ($0.91) | -14.91 |
| Acelyrin | N/A | N/A | -$381.64 million | ($2.46) | -0.79 |
Analyst Ratings
This is a summary of recent recommendations for Evolus and Acelyrin, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evolus | 0 | 0 | 4 | 0 | 3.00 |
| Acelyrin | 0 | 3 | 2 | 0 | 2.40 |
Evolus currently has a consensus target price of $23.67, suggesting a potential upside of 74.40%. Acelyrin has a consensus target price of $9.60, suggesting a potential upside of 394.85%. Given Acelyrin’s higher probable upside, analysts plainly believe Acelyrin is more favorable than Evolus.
Volatility and Risk
Evolus has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Acelyrin has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500.
Profitability
This table compares Evolus and Acelyrin’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evolus | -22.33% | -847.60% | -22.15% |
| Acelyrin | N/A | -44.12% | -39.02% |
Summary
Evolus beats Acelyrin on 7 of the 13 factors compared between the two stocks.
About Evolus
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
About Acelyrin
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.
